1 unchanged sentence
Unregistered Sales of Equity Securities
−Removed: Issuer Purchases of Equity Securities
−Removed: On October 30, 2023, pursuant to a Common Stock Repurchase Agreement with vTv Therapeutics, we repurchased 576,443 shares of our common stock from vTv Therapeutics at a price of $7.64 per share for an aggregate purchase price of approximately $4.4 million.
−Removed: The repurchase was made directly in a private, non-underwritten transaction.
−Removed: Subsequently, we retired the repurchased shares.
Use of Proceeds
1 unchanged sentence
333-254534) that was declared effective on April 8, 2021 and registered an aggregate of 7,187,500 shares of our common stock.
−Removed: On April 13, 2021, we completed our IPO and sold 6,250,000 shares of our common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $93.8 million before deducting underwriters’
−Removed: discounts and commissions and offering-related expenses.
+Added: On April 13, 2021, we completed our IPO and sold 6,250,000 shares of our common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $93.8 million before deducting underwriters’ discounts and commissions and offering-related expenses.
Net proceeds, after deducting underwriting discounts and commissions of $6.6 million and offering expenses of approximately $2.6 million, were $84.6 million.
−Removed: Jefferies LLC, Leerink and Piper Sandler & Co.
+Added: Jefferies LLC, SVB Securities LLC (now Leerink Partners LLC) and Piper Sandler & Co.
acted as joint book-running managers.
−Removed: As of September 30, 2023, we have used approximately $23.8 million of the net proceeds from our IPO.
+Added: As of March 31, 2024, we have used approximately $66.6 million of the net proceeds from our IPO.
We have invested the remaining net proceeds in highly liquid money market funds and short-term investments.
−Removed: The remaining net proceeds from the IPO will be used, together with our cash, cash equivalents, and short-term
−Removed: investments, to fund continued research and development of mavodelpar in patients with PMM and LC-FAOD, other clinical trials and preclinical studies, and commercial readiness preparations, and to provide funds for working capital and other general purposes.
+Added: The remaining net proceeds from the IPO will be used to fund our operations.
None of the offering proceeds were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.